-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new version of the National Medical Insurance Catalogue will be officially launched nationwide from March 1
Exenatide is the first GLP-1 receptor agonist approved by the FDA.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
On October 30, 2009, Amylin announced that Exenatide has been approved by the FDA as a single drug for blood glucose control in type 2 diabetes .
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon .
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs .
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69% .
According to data from Meinenet, the amount of Exenatide (Byetta) used in public hospitals in key provinces and cities in China fell below 10 million yuan in 2020, down 42.
90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market .
Exenatide injection can improve the level of blood sugar control, protect β cells, delay the course of the disease, and reduce the risk of hypoglycemia and weight gain .
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval .
At present, the original research is exclusive, and the generic drugs are stepping up the layout
The market is declining, and new formulations are unstoppable
Exenatide is the first GLP-1 receptor agonist approved by the FDA.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
On October 30, 2009, Amylin announced that Exenatide has been approved by the FDA as a single drug for blood glucose control in type 2 diabetes .
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon .
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs .
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69% .
According to data from Meinenet, the amount of Exenatide (Byetta) used in public hospitals in key provinces and cities in China fell below 10 million yuan in 2020, down 42.
90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market .
Exenatide injection can improve the level of blood sugar control, protect β cells, delay the course of the disease, and reduce the risk of hypoglycemia and weight gain .
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval .
